Anbio Biotechnology Class A Ordinary Shares (NNNN)
Valuation Overview•Is Anbio Biotechnology Class A Ordinary Shares Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
High-quality fundamentals with a strong composite quality score of 84/100, backed by robust profitability and solvency.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: High-quality compounder, with solvency as the only relative weakness.
Wall Street sentiment is generally neutral. The company currently retains all capital for reinvestment and growth rather than returning it to shareholders.
NNNN exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins (highlighted by a massive 28.3% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($12M) and minimal debt risk.
The company is driving exceptional top-line expansion (22.7% 3Y CAGR) paired with highly explosive earnings growth (30.2% EPS 3Y CAGR). This growth is supported by elite operational efficiency, sustaining an impressive 26.5% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | +21.9% | +22.7% | — | — | |
| EBITDA | -$1.3M | — | +0.4% | — | — | |
| Net Income | -$1.3M | +5.3% | -2.2% | — | — | |
| EPS (Diluted) | $-0.03 | +366.7% | +30.2% | — | — | |
| Free Cash Flow | $1.6M | +131.6% | -20.8% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 62.1% | 58.4% | 58.2% | 58.2% |
| Operating Margin | 26.5% | 32.3% | 38.1% | 38.1% |
| Net Margin | 31.0% | 35.0% | 40.6% | 40.6% |
| FCF Margin | 20.0% | 19.2% | 38.0% | 38.0% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | — | $0.07 | — |
Total return is +43.9% (1Y), outperforming the benchmark by +19.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -43.6% | -52.9% | — |
| 1Y | +43.9% | +19.0% | — |
| 3YCAGR | +42.3% | +22.5% | — |
| 5YCAGR | +23.6% | +11.0% | — |
| 10YCAGR | +11.2% | -2.5% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Anbio Biotechnology Class A Ordinary Shares (NNNN) valuation, health, and returns.
Anbio Biotechnology Class A Ordinary Shares valuation is being assessed using available models.
Valuation anchors are currently not available.
Anbio Biotechnology Class A Ordinary Shares displays excellent financial health with a composite quality score of 84/100, supported by a Altman Z-Score of 100.0 (safe zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 28.3%.
Anbio Biotechnology Class A Ordinary Shares does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Anbio Biotechnology Class A Ordinary Shares's current growth trajectory is Stable. The company achieved +21.9% 1Y revenue growth and +366.7% 1Y EPS growth, compared to its 3Y revenue CAGR of +22.7%.
Wall Street consensus is Hold based on 0 analysts. The consensus price target represents a N/A change from current levels.
Investment risks for Anbio Biotechnology Class A Ordinary Shares include: -76.4% 1-year max drawdown. Volatility risk is characterized by a beta of 0.67x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.